An Open Label, Single Arm, Multicenter Study to Evaluate the Effect of Voxelotor on Cerebral Blood Flow and Neurocognitive Function in Adolescents and Adults With Sickle Cell Disease
Latest Information Update: 14 May 2024
At a glance
- Drugs Voxelotor (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Sponsors Pfizer
- 08 Mar 2024 Status changed from active, no longer recruiting to withdrawn prior to enrolment due to Sponsor's business reasons and neither because of any safety concerns nor due to change in the benefit-risk ratio.
- 01 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2023 The protocol was ameded to decrease in arm size from 2 to 1 and extension of study time Frame to 24 Weeks along with change in masking to open lable.